Amgn) and AstraZeneca’s (.
NASDAQ
Tezspire (tezepelumab) can now be used to treat bronchial asthma in patients with severe or refractory disease in whom asthma symptoms cannot be controlled with mid- or high-dose inhaled corticosteroids and other long-term maintenance therapies, AstraZeneca said in a Sept. 27 press release.
Earlier in September, Tezspire was approved in the EU as an add-on maintenance therapy for patients 12 years and older with severe asthma.
The drug is already approved in the U.S. and certain other countries for treating severe asthma.
AZN +0.66% to $53.37 premarket Sept. 27.
mobilenewspepar.com.
MobileNewspeparhttp